One of them is already a leader in the market for weight management drugs, and the other could join this field.

Working-age Americans who get health insurance through their job will see largest health insurance rate hikes since 2010.

The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.

As evidence grows supporting the potential health benefits of obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound, so too — frustratingly — do the barriers to accessing them.

This Denmark-headquartered company underestimated demand for its anti-obesity treatment Wegovy when it launched in the U.S.

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it ...

Novo Nordisk will lay off 9,000 employees worldwide as part of a restructuring plan, redirecting savings to diabetes and obesity drug growth.

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...

The restructuring, which would eliminate 11% of the company's workforce, aimed to reduce organizational complexity and speed ...

Novo Nordisk , the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to ...